QUEST DIAGNOSTICS INCORPORATED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.7 USD | -2.09% |
|
+7.40% | -1.92% |
| 12:59pm | Labcorp beats quarterly estimates on strong testing demand | RE |
| Apr. 24 | Jefferies Adjusts Price Target on Quest Diagnostics to $160 From $155 | MT |
Financials (USD)
| Sales 2024 * | 9.45B | Sales 2025 * | 9.75B | Capitalization | 15.28B |
|---|---|---|---|---|---|
| Net income 2024 * | 894M | Net income 2025 * | 960M | EV / Sales 2024 * | 2.05 x |
| Net Debt 2024 * | 4.07B | Net Debt 2025 * | 3.44B | EV / Sales 2025 * | 1.92 x |
| P/E ratio 2024 * |
17.6
x | P/E ratio 2025 * |
16.1
x | Employees | 50,000 |
| Yield 2024 * |
2.1% | Yield 2025 * |
2.16% | Free-Float | 68.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Quest Diagnostics Incorporated
More recommendations
More press releases
More news
| 1 day | +0.62% | ||
| 1 week | +8.32% | ||
| Current month | +3.34% | ||
| 1 month | +6.38% | ||
| 3 months | +7.66% | ||
| 6 months | +11.30% | ||
| Current year | -0.24% |
1 week
126.08
138.91
1 month
125.42138.91
Current year
123.04143.63
1 year
119.59147.97
3 years
119.59174.16
5 years
73.02174.16
10 years
54.90174.16
| Managers | Title | Age | Since |
|---|---|---|---|
James Davis
CEO | Chief Executive Officer | 61 | 13-03-31 |
Sam Samad
DFI | Director of Finance/CFO | 54 | 22-07-10 |
Kristin Wallace
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Denise Morrison
BRD | Director/Board Member | 70 | 19-02-17 |
Timothy Ring
BRD | Director/Board Member | 66 | 11-12-06 |
Gail Wilensky
BRD | Director/Board Member | 80 | 96-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.84% | 215 M€ | +11.68% | - | |
| 2.17% | 2 M€ | +5.19% | ||
| 2.05% | 8 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 135.2 | -1.74% | 362 452 |
| 24-04-24 | 137.6 | +0.62% | 1,566,638 |
| 24-04-23 | 136.7 | +5.08% | 2,088,321 |
| 24-04-22 | 130.1 | +1.28% | 1,694,278 |
| 24-04-19 | 128.4 | +2.01% | 1,557,641 |
Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT
More quotes
Quest Diagnostics is the world's leading provider of diagnostics testing and information service for patients and health professionals. Net sales break down by activity as follows:
- testing and diagnostic services (97.3%): routine clinical testing, gene-based testing and advanced diagnostic and anatomica pathology diagnostic services;
- other (2.7%).
Calendar
2024-07-23
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
137.6
USD
Average target price
146
USD
Spread / Average Target
+6.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.24% | 15.28B | |
| -14.17% | 85.42B | |
| +17.86% | 84.38B | |
| +10.92% | 29.39B | |
| -8.51% | 17.49B | |
| -2.32% | 16.44B | |
| -2.31% | 11.71B | |
| +1.08% | 12.22B | |
| -31.23% | 11.98B | |
| +26.71% | 11.64B |
- Stock Market
- Equities
- DGX Stock
